Livzon Pharma Leads $25.5 Million Funding of Cynvenio Biosystems

Livzon Pharma of Zuhai, China led a $25.5 million Series B funding of Cynvenio Biosystems, a Los Angeles area diagnostics company. Cynvenio is developing LiquidBiopsy, a technology that performs genomic analyses of circulating tumor cells from whole blood. Last month, Livzon said it invested $10 million in Cynvenio's Series B and committed another $10 million to form a China JV with Cynvenio. Also participating in the B round was Greenwoods Private Equity Funds (Shanghai) and Syno Capital (New York), among others. More details.... Stock Symbols: (SZ: 000513 HK: 01513) Share this with colleagues: // //